The current advances in coronary MR (CMR) make it the strongestmodality for coronary imaging, according to Michael McDonnell, MD,associate professor of the cardiovascular institute at StanfordUniversity School of Medicine.

At the 16th annual nurse and technologist symposium at theTranscatheter Cardiovascular Therapeutics (TCT) conference inWashington, D.C., this week, three different cardiologists made thecase for varying modalities, including CT, MR and other unique invasiveimaging modalities, in the lecture series “Non-invasive Imaging in anInvasive World.”

Astellas Pharma of Tokyo and King Pharmaceuticals of Bristol, Tenn.,have settled patent disputes with Teva Pharmaceutical Industries ofJerusalem.

Cardiac CT angiography (CCTA) can safely triage low-risk, acute chestpain patients and it remains particularly effective because it reducesthe length of stay in a hospital and pain for the patient, according toa presentation this weekend at the Transcatheter CardiovascularTherapeutics (TCT) conference in Washington, D.C.

Hybrid methods and modalities are the most effective in attainingcardiovascular images, according to a lecture given by Daniel Berman,MD, chief of cardiac imaging and nuclear cardiology during “The Latest Advances in Cardiovascular CT” on Saturday at theTranscatheter Cardiovascular Therapeutics (TCT) conference inWashington, D.C.

A few cutting-edge sites outline their 64-slice CT data management plans to help steer their colleagues toward an optimal solution.

Cordis, a subsidiary of Johnson & Johnson, has introduced its FireStar Rx PTCA Dilatation Catheter and its Dura Star Rx PTCA DilatationCatheter into the U.S. market.

In a warning letter sent on Aug. 30, the U.S. FDA said that BostonScientific committed serious violations in conducting a clinical trialwhen it failed to report two participant deaths.